The cholinesterase inhibitors (ChEIs) and memantine have become established as first steps in changing Alzheimer's disease (AD) from a disease for which there was no effective pharmacotherapy to a disease for which there is treatment. These agents provide detectable symptomatic improvement and have a modest impact on the progression of the disease from mild cognitive impairment (MCI) to disabling dementia and death. Nonetheless, the therapeutic limitations of the currently approved drugs, as well as the steadily increasing prevalence of the disease, have led to increased basic and clinical research aimed at developing better medications for the treatment of AD. Several drugs with widely differing targets are currently in development, some discovered serendipitously, some designed rationally based on evolving knowledge of the pathophysiology of AD, and some identified from epidemiologic research. To date, however, no novel agent has successfully cleared the gauntlet of all phases of the clinical development process. Much focus has been on amyloid-based approaches in recent years. Nevertheless, given the complexity of the disease, other therapeutic targets are being considered and developed.

We invite investigators to contribute original research articles as well as review articles that will stimulate the continuing efforts to describe and develop innovative and novel therapeutics for AD. We are particularly interested in articles describing the new and emerging treatments and targets for AD. Potential topics include, but are not limited to:

• Beta secretase inhibitors
• Gamma secretase inhibitors
• Tangle and tau-based approaches
• Novel anti-inflammatories
• Amyloid clearance enhancers
• Aggregation inhibitors
• Gene therapies
• Neurotransmitter-based approaches
• Novel acetylcholinesterase inhibitors
• Immunotherapies
• sRAGE antagonists

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/ijad/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable: